Literature DB >> 14996089

Inhibitory influences of xanthine oxidase inhibitor and angiotensin I-converting enzyme inhibitor on multinucleated giant cell formation from monocytes by downregulation of adhesion molecules and purinergic receptors.

K Mizuno1, H Okamoto, T Horio.   

Abstract

BACKGROUND: Allopurinol, a xanthine oxidase inhibitor, and captopril, an inhibitor of angiotensin I-converting enzyme, are widely used for hyperuricaemia and hypertension, respectively. There have been reported cases showing that these two agents are effective for the treatment of granulomatous diseases such as sarcoidosis, although the mode of action is not elucidated.
OBJECTIVES: We examined the in vitro effects of these agents on the formation of multinucleated giant cells (MGC) from human monocytes by concanavalin A-stimulated mononuclear cell supernatants (conditioned medium).
METHODS: We cultured monocytes with conditioned medium and each agent and compared the rate of MGC formation as well as the expression of adhesion molecules and P2X7 receptor, which are involved in MGC formation.
RESULTS: The addition of 25 or 100 microg mL(-1) allopurinol or 0.125-1.0 microg mL(-1) captopril inhibited MGC formation. Monocytes treated with these agents exhibited less expression of intercellular adhesion molecular-1 (ICAM-1) than untreated monocytes. The susceptibility of monocytes cultured in conditioned medium for 24 h to 2'-and 3'-o-(4-benzoyl-benzoyl)adenosine triphosphate-mediated cytolysis was significantly lower in monocytes treated with these agents than in untreated monocytes.
CONCLUSIONS: Allopurinol and captopril have a therapeutic effect on granulomatous disorders by a direct action on monocyte/macrophage lineage cells partly through downregulation of ICAM-1 and P2X7 receptor.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14996089     DOI: 10.1111/j.1365-2133.2004.05768.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  7 in total

Review 1.  Role of NADPH oxidase in formation and function of multinucleated giant cells.

Authors:  Mark T Quinn; Igor A Schepetkin
Journal:  J Innate Immun       Date:  2009-07-07       Impact factor: 7.349

Review 2.  Evidence-based therapy for cutaneous sarcoidosis.

Authors:  Christy B Doherty; Ted Rosen
Journal:  Drugs       Date:  2008       Impact factor: 9.546

3.  Sequential combined treatment with allopurinol and benznidazole in the chronic phase of Trypanosoma cruzi infection: a pilot study.

Authors:  D E Perez-Mazliah; M G Alvarez; G Cooley; B E Lococo; G Bertocchi; M Petti; M C Albareda; A H Armenti; R L Tarleton; S A Laucella; R Viotti
Journal:  J Antimicrob Chemother       Date:  2012-10-26       Impact factor: 5.790

Review 4.  Unconventional uses of common conventional drugs: A review.

Authors:  Anupam Das; Abheek Sil; Shouvik Ghosh; Saumya Panda
Journal:  Indian J Dermatol Venereol Leprol       Date:  2021 Jul-Aug       Impact factor: 2.545

5.  Allopurinol reduces antigen-specific and polyclonal activation of human T cells.

Authors:  Damián Pérez-Mazliah; María C Albareda; María G Alvarez; Bruno Lococo; Graciela L Bertocchi; Marcos Petti; Rodolfo J Viotti; Susana A Laucella
Journal:  Front Immunol       Date:  2012-09-21       Impact factor: 7.561

6.  The role of the purinergic P2X7 receptor in inflammation.

Authors:  Martin F Lister; John Sharkey; Deborah A Sawatzky; Joseph P Hodgkiss; Donald J Davidson; Adriano G Rossi; Keith Finlayson
Journal:  J Inflamm (Lond)       Date:  2007-03-16       Impact factor: 4.981

7.  Xanthine Oxidase Inhibitor Febuxostat Exerts an Anti-Inflammatory Action and Protects against Diabetic Nephropathy Development in KK-Ay Obese Diabetic Mice.

Authors:  Yu Mizuno; Takeshi Yamamotoya; Yusuke Nakatsu; Koji Ueda; Yasuka Matsunaga; Masa-Ki Inoue; Hideyuki Sakoda; Midori Fujishiro; Hiraku Ono; Takako Kikuchi; Masahiro Takahashi; Kenichi Morii; Kensuke Sasaki; Takao Masaki; Tomoichiro Asano; Akifumi Kushiyama
Journal:  Int J Mol Sci       Date:  2019-09-21       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.